-
Tomaralimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)
Quick Facts About TomaralimabWhat is Tomaralimab?Tomaralimab is an anti-CD47 monoclonal antibody designed to enhance immune system recognition of cancer cells by blocking the "don't eat
Ulviprubart: A Breakthrough in Autoimmune Disease Treatment(Post)Quick Facts About UlviprubartWhat is Ulviprubart?Ulviprubart is an experimental complement inhibitor designed to modulate immune responses in autoimmune diseases.What is the mechanism of
Neuroinflammation and Compulsive Behavior: The Role of Astrocytes in OCD(Post)Imagine a mind trapped in a loop, endlessly repeating actions or thoughts, driven by an invisible force. For millions worldwide, this is the reality of Obsessive-Compulsive Disorder (OCD). While trad
Enfortumab Vedotin: Unveiling Its Role in Cancer Treatment and the Rise of Biosimilars(Post)Quick Facts About EnfortumabWhat is Enfortumab Vedotin?Enfortumab vedotin is an innovative cancer therapy, primarily used in treating urothelial carcinoma (bladder cancer) that has not r
Uliledlimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About UliledlimabWhat is Uliledlimab?Uliledlimab is a monoclonal antibody targeting CD47, a checkpoint protein that helps tumors evade immune system detection. By blocking CD
Apamistamab: Advancing Leukemia Treatment through Targeted Radioimmunotherapy(Post)Quick Facts About ApamistamabWhat is Apamistamab?Apamistamab is a monoclonal antibody that targets the CD45 antigen on hematopoietic cells.How does Apamistamab work?When labeled with the
Unlocking the Next Wave of Cancer Treatment: The Promise and Progress of CAR-T Cell Therapy(Post)Imagine a living drug, engineered from a patient's own immune system, that can hunt down and destroy cancer cells with remarkable precision. This isn't science fiction; it's the reality of Chimeric An
In Vivo CAR-T Engineering: The Dawn of Off-the-Shelf Immunotherapy(Post)Imagine a future where cancer treatment isn't a grueling, months-long process involving cell extraction and reinfusion, but a simple, targeted injection that reprograms your body's own immune cells t
The Bioelectronic Revolution: How Vagus Nerve Stimulation is Redefining Autoimmune Therapy(Post)Imagine a future where chronic autoimmune diseases, once managed by powerful pharmaceuticals with challenging side effects, are instead calmed by a gentle electrical pulse. This isn't science fiction
Immunohistochemistry Protocol Guide - Mandarin(Page)免疫组织化学规程指南(IHC,中文) | Assay Genie
Lemzoparlimab: Targeting CD47 for Cancer Immunotherapy Advancements(Post)Quick Facts About LemzoparlimabWhat is Lemzoparlimab?Lemzoparlimab is a monoclonal antibody that targets CD47, a protein known for its role in helping tumors evade the immune system. By
Alsevalimab: Targeting CD47 for Cancer Research and Treatment(Post)Quick Facts About AlsevalimabWhat is Alsevalimab?Alsevalimab is a monoclonal antibody targeting CD47, a protein involved in immune evasion by cancer cells. By blocking CD47, Alsevalimab
Lorvotuzumab: Targeting CD56 in Cancer Research and Therapeutic Development(Post)Quick Facts About LorvotuzumabWhat is Lorvotuzumab?Lorvotuzumab is an antibody-drug conjugate (ADC) designed to target CD56, a surface antigen commonly overexpressed in neuroendocrine tu
Pamrevlumab: Unveiling the Potential of Anti-Fibrotic Therapy in Clinical Trials and Research(Post)Quick Facts About PamrevlumabWhat is Pamrevlumab?Pamrevlumab (FG-3019) is a monoclonal antibody designed to target and inhibit the connective tissue growth factor (CTGF), a key driver of
Fletikumab: Unlocking the Potential of Anti-CD47 Therapy in Cancer Research(Post)Quick Facts About FletikumabWhat is Fletikumab?Fletikumab is an investigational monoclonal antibody targeting CD47, a key immune checkpoint that enables cancer cells to evade immune dest
ELISA バッファーとレシピ(Page)ELISA バッファーとレシピ | Assay Genie | Assay Genie
Ivuxolimab: Redefining Cancer Immunotherapy and Research(Post)Quick Facts About IvuxolimabWhat is ivuxolimab?Ivuxolimab is a monoclonal antibody targeting CD47, a "don't eat me" signal that cancer cells exploit to evade immune destruction.How does
Lirilumab: Unlocking the Potential of Anti-KIR Therapy in Cancer Research(Post)Quick Facts About LirilumabWhat is Lirilumab?Lirilumab is an anti-KIR monoclonal antibody designed to enhance natural killer (NK) cell activity by blocking killer-cell immunoglobulin-lik
Emapalumab: Unlocking the Potential of Targeting IFN-γ in HLH Treatment(Post)Quick Facts About EmapalumabWhat is Emapalumab?Emapalumab is a fully human monoclonal antibody that neutralizes interferon-gamma (IFN-γ). It is the first FDA-approved therapy for primary
Cabiralizumab: Unlocking the Potential of Anti-CSF1R Therapy(Post)What You Need to Know About CabiralizumabWhat is Cabiralizumab?Cabiralizumab is a monoclonal antibody targeting the colony-stimulating factor-1 receptor (CSF1R), developed for treating c
Eldelumab: Unlocking the Potential of Anti-TNFSF14 in Inflammatory Diseases(Post)Quick Facts About EldelumabWhat is Eldelumab?Eldelumab is a monoclonal antibody targeting TNFSF14 (LIGHT), a key regulator in immune system signaling, with potential applications in infl
Next-Generation Cancer Therapy: Harnessing CAR-T Cells and the Tumor Microenvironment(Post)For decades, the fight against cancer has been a relentless battle of attrition, often with treatments that harm the body as much as the disease. But a new era of precision medicine is dawning, one th
Calculer et valider la limite de détection d'un ELISA en laboratoire(Post)Calculer et valider la limite de détection d’un ELISA en laboratoire La limite de détection (LOD) d’un ELISA se calcule classiquement comme la moyenne des blancs plus 3 fois leur écart-type, et cette
Cevostamab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Info Section: Key Facts About CevostamabWhat is Cevostamab?Cevostamab is an investigational monoclonal antibody targeting CD47, a cell surface protein that helps cancer cells evade
Glenzocimab: A Novel Antiplatelet Therapy for Stroke Prevention(Post)Quick Facts About GlenzocimabWhat is Glenzocimab?Glenzocimab is an innovative monoclonal antibody designed to reduce the risk of ischemic stroke by selectively targeting platelet glycopr
Canakinumab: Unraveling Its Role in Inflammatory Disease and Cancer Research(Post)Quick Facts About CanakinumabWhat is Canakinumab?Canakinumab is a human monoclonal antibody that targets interleukin-1 beta (IL-1β), reducing inflammation associated with various disease
세포 용해를위한 소니케이션(초음파 처리 분해) 프로토콜 (Page) Unlocking the Potential of Anti-CD47 in Cancer Immunotherapy(Post)Quick Facts About RagifilimabWhat is Ragifilimab?Ragifilimab is an investigational anti-CD47 monoclonal antibody developed to block the CD47-SIRPα interaction, thereby enhancing macropha
Secukinumab: A Comprehensive Guide to Its Mechanism, Applications, and Biosimilar Advancements(Post)Quick Facts About SecukinumabWhat is SecukinumabSecukinumab is a monoclonal antibody that targets interleukin-17A (IL-17A), a key cytokine involved in inflammatory and autoimmune respons
Bridging ELISA sicher validieren: Praxisleitfaden für Antikörpernachweis(Post)Bridging ELISA sicher validieren: Praxisleitfaden für Antikörpernachweis Für den routinemäßigen Nachweis von Anti‑Drug‑Antikörpern ist das Bridging‑ELISA das gängigste Format, weil es isotypunabhängi
Plozalizumab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Info Section: Key Facts About PlozalizumabWhat is Plozalizumab?Plozalizumab is an investigational monoclonal antibody that targets CD47, a key immune checkpoint in cancer cells. By
Six étapes pour un protocole ELISA sandwich reproductible en laboratoire(Post)Le protocole ELISA sandwich standard suit six étapes: revêtement du puits avec l’anticorps de capture, blocage, incubation des standards et échantillons, ajout de l’anticorps de détection, puis du
Rosopatamab: Unveiling the Potential of Anti-CD47 Therapy in Cancer Research(Post)Quick Facts About RosopatamabWhat is Rosopatamab?Rosopatamab is a monoclonal antibody targeting CD47, a critical immune checkpoint that helps cancer cells evade immune detection. By bloc
Mogamulizumab: Understanding Its Mechanism, Clinical Applications, and the Role of Biosimilars in Research(Post)Quick Info Section: Key Facts About MogamulizumabWhat is Mogamulizumab?Mogamulizumab is an anti-CCR4 monoclonal antibody used primarily for treating certain cancers, including cutaneous
3D Organoid Cell Viability Assay: Assessing Environmental Stress on BENOs for Live Delivery(Post)3D Organoid Cell Viability Assay (AKES081) effectively measures BENO model viability across different storage conditions. AKES081 detects significant viability differences, particularly
Praluzatamab: Unveiling the Promise of CD47-Targeted Therapy in Cancer Research(Post)Quick Facts About PraluzatamabWhat is Praluzatamab?Praluzatamab is an experimental monoclonal antibody that targets CD47, a “don’t eat me” signal used by cancer cells to evade immune des
Ferroptosis: A New Frontier in Cancer Therapy(Post)For decades, the primary strategy in cancer treatment has been to trigger apoptosis, a form of programmed cell death, in malignant cells. However, many cancers develop resistance to apoptosis-inducin
Vixarelimab: A Novel Approach to Targeting Prurigo Nodularis and Fibrosis(Post)Quick Facts About VixarelimabWhat is Vixarelimab?Vixarelimab is an investigational monoclonal antibody developed to target oncostatin M receptor beta (OSMRβ), a key pathway involved in p
Tumor-Associated Macrophages: Double Agents in the Cancer Battlefield(Post)Tumor-Associated Macrophages: Double Agents in the Cancer Battlefield In the intricate theater of the human body, the immune system acts as a vigilant guardian, dispatching cellular soldiers to seek
Denosumab: A Comprehensive Overview of Mechanism, Applications, and Research Advances(Post)Biologics · Bone MetabolismDenosumab: RANKL Inhibition, Clinical Applications and BiosimilarsDenosumab is a fully human monoclonal antibody against RANKL, the cytokine that drives osteoclast formation
Monalizumab: A Breakthrough in Cancer Immunotherapy Targeting NKG2A(Post)Quick Facts About MonalizumabWhat is Monalizumab?Monalizumab is a first-in-class immune checkpoint inhibitor targeting NKG2A, developed to enhance anti-tumor immune response by blocking
Galegenimab: Unlocking the Potential of Anti-CD47 in Cancer Research(Post)Quick Facts About GalegenimabWhat is Galegenimab?Galegenimab is an anti-CD47 monoclonal antibody designed to block the "don't eat me" signal, enhancing the immune system's ability to eli
ELISA Troubleshooting: Why You Can't Skip the Full Standard Curve(Post)Quick answer A researcher measuring dopamine in mouse brain tissue got no detectable signal and, with many samples to run, asked whether the full standard curve could be skipped to sav
In Vivo Cell Depletion: Antibody Targets, Fc Mechanisms and Dosing(Post)A depletion experiment is only as good as the depletion you can prove. Injecting a functional-grade antibody and assuming the population is gone is the most common failure mode in in vivo immunology.
TCA Cycle Assays(Page) mRNA-1010 and Beyond: How Moderna's mRNA Platform is Revolutionizing Hantavirus Vaccine Development(Post)Hantavirus, a silent threat lurking in rodent populations, has long posed a significant public health challenge with its severe and often fatal outcomes. For decades, the quest for effective vaccines
ELISA 분석법, 원리, 프로토콜, 방법 및 키트(Page) Immune Cell 'Bloodhounds': Engineering Metabolite-Sensing Receptors to Infiltrate Solid Tumors(Post)Imagine an elite squad of soldiers sent to neutralize a hidden fortress, only to find themselves wandering aimlessly in a thick, disorienting fog just outside the gates. This is the current reality f
Comment choisir une protéine cytokine pour votre étude(Post)Comment choisir une protéine cytokine pour votre étude Pour une mesure fonctionnelle in vitro, privilégiez une cytokine recombinante à activité biologique validée sur la lignée cible. Pour une admini
Comment choisir un panel cytokines selon votre objectif(Post)Comment choisir un panel cytokines selon votre objectif Pour une sensibilité extrême sur un nombre restreint d’analytes, privilégiez une plateforme ultra-sensible comme SIMOA. Pour multiplexer largem
3–5 Waschgänge: Waschpuffer im ELISA für Forschende optimieren(Post)3–5 Waschgänge: Waschpuffer im ELISA für Forschende optimieren Verwenden Sie für ELISA-Anwendungen einen speziell dafür formulierten Waschpuffer auf PBS- oder TuS-Basis mit einem milden Detergens wie
Anticorps pour IHC : la checklist de validation qui compte(Post)Anticorps pour IHC : la checklist de validation qui compte Pour l’IHC, n’utilisez jamais un anticorps sans preuve de performance sur un tissu comparable au vôtre, sans contrôles positifs et négatifs
Estabilidad de anticuerpos: métodos, criterios y errores de interpretación(Post)Estabilidad de anticuerpos: métodos, criterios y errores de interpretación La estabilidad de anticuerpos se confirma cruzando dos evidencias, nunca una sola: integridad físico-química (temperatura de
How Cancer Cells Hijack Immune Defenses Through Mitochondrial Transfer(Post)Imagine a battlefield where the enemy doesn't just hide from soldiers—it actively sabotages their weapons. In the tumor microenvironment, cancer cells have evolved a devious strategy: they transfer th
CV en ELISA : 5 vérifications pour techniciens si le %CV > 10 %(Post)CV en ELISA : 5 vérifications pour techniciens si le %CV > 10 % Le %CV en ELISA se calcule ainsi : (écart-type ÷ moyenne) × 100. Visez un CV intra-plaque inférieur à 10 % (idéalement sous 8 %) et un